Healthcare -
Biotechnology - NASDAQ - GB
$ 0.5799
-1.71 %
$ 148 M
Market Cap
-3.41
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Adaptimmune Therapeutics plc
| Revenue | 60.3 M |
| Cost Of Revenue | 9.86 M |
| Gross Profit | 50.4 M |
| Operating Expenses | 188 M |
| Operating Income | -138 M |
| Other Expenses | -24.2 M |
| Net Income | -114 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Jun-2015 | Jun-2014 | Jun-2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Revenue | 60.3 | 27.1 | 6.1 | 4.0 | 1.1 | 59.5 | 37.8 | 14.2 | 10.7 | 0.6 | 0 |
| GROSS PROFIT | |||||||||||
| Cost Of Revenue | 9.9 | 127.7 | 111.1 | 91.6 | 97.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 50.4 | (100.6) | (104.9) | (87.6) | (96.4) | 59.5 | 37.8 | 14.2 | 10.7 | 0.6 | 0 |
| OPERATING INCOME | |||||||||||
| Operating Expenses | 188.4 | 191.1 | 168.4 | 137.4 | 140.9 | 141.9 | 118.5 | 87.0 | 33.8 | 15.0 | 9.4 |
| Selling, General and Administrative Expenses | 71.8 | 63.4 | 57.3 | 45.8 | 43.4 | 43.6 | 31.1 | 23.2 | 11.3 | 2.7 | 1.2 |
| Research and Development Expenses | 126.5 | 127.7 | 111.1 | 91.6 | 97.5 | 98.3 | 87.4 | 63.8 | 23.2 | 12.5 | 8.1 |
| Operating Income | (138.0) | (164.0) | (162.2) | (133.4) | (139.8) | (82.4) | (80.7) | (72.8) | (23.1) | (14.4) | (9.4) |
| PRE-TAX INCOME | |||||||||||
| Interest Income Expense | 0 | 0 | 0 | 0 | 0 | 0.4 | 2.2 | 0 | 0 | 6.81 K | 6.08 K |
| Total Other Income | 25.5 | (1.3) | 4.9 | 3.5 | 2.8 | (12.7) | 11.0 | 2.1 | (3.2) | 2.8 | 5 K |
| Pre-Tax Income | (112.5) | (163.0) | (157.3) | (129.9) | (136.9) | (95.0) | (69.7) | (70.7) | (23.7) | (14.4) | (9.3) |
| NET INCOME | |||||||||||
| Tax Provision | 1.3 | 2.5 | 0.8 | 0.2 | 0.2 | 0.5 | 0.5 | 0.9 | (2.1) | (1.7) | (0.9) |
| Net Income | (113.9) | (165.5) | (158.1) | (130.1) | (137.2) | (95.5) | (70.1) | (71.6) | (21.6) | (12.7) | (8.5) |
| EPS | 0.57 | 1.03 | 1.01 | 0.91 | 1.31 | 0.98 | 0.8 | 1.01 | 0.6 | 0.0299 | 0.0199 |